Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Rein Therapeutics ( (RNTX) ) is now available.
On July 10, 2025, Rein Therapeutics‘ Board of Directors amended the company’s by-laws to establish a quorum requirement of 40% of voting shares present for stockholder meetings. Earlier, on June 10, 2025, the FDA placed a clinical hold on the company’s Phase 2 RENEW trial for its IPF treatment candidate, LTI-03, due to safety concerns. The company plans to address these concerns and resume the trial.
The most recent analyst rating on (RNTX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.
Spark’s Take on RNTX Stock
According to Spark, TipRanks’ AI Analyst, RNTX is a Underperform.
Rein Therapeutics is experiencing severe financial difficulties, with persistent negative net income and cash flows. The technical analysis suggests bearish momentum with potential near-term volatility. The negative P/E ratio and lack of dividends further highlight the company’s weak financial position. The overall outlook for the stock is challenging, with significant risks outweighing potential rewards.
To see Spark’s full report on RNTX stock, click here.
More about Rein Therapeutics
Rein Therapeutics, Inc. operates in the pharmaceutical industry, focusing on the development of treatments for idiopathic pulmonary fibrosis (IPF). The company’s primary product candidate is LTI-03, which is currently undergoing clinical trials.
Average Trading Volume: 38,375
Technical Sentiment Signal: Sell
Current Market Cap: $33.01M
See more insights into RNTX stock on TipRanks’ Stock Analysis page.